Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight
Christine M. Mack, David G. Parkes(Amplyx Pharmaceuticals (United States)), Jennifer Athanacio(Amplyx Pharmaceuticals (United States)), Stacy Guss(Amplyx Pharmaceuticals (United States)), Calvin Vu, Jonathan D. Roth(Rutgers, The State University of New Jersey), Julie Wilson, James M. Reynolds(Amplyx Pharmaceuticals (United States)), Kevin D. Laugero(Agricultural Research Service)
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
September 14, 2007
Cited by 109
Related Papers
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
|Proceedings of the National Academy of Sciences|2008|433
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395
Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2013|294
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2012|278